Blog
RSS FeedPosted by Michael Wonder on 03 Oct 2016
NICE says no to daclizumab (Zinbryta)
3 October 2016 - The MS Trust is disappointed that NICE does not intend to recommend that daclizumab (Zinbryta) be made ...
Posted by Michael Wonder on 26 Aug 2016
New Brunswick includes Lemtrada (alemtuzumab) on provincial drug program for eligible patients
25 August 2016 - Unique treatment delivered in only two cycles one year apart. ...
Posted by Michael Wonder on 06 Jul 2016
Saskatchewan includes Lemtrada (alemtuzumab) on MS Drugs Program for eligible patients
5 July 2016 - Unique treatment delivered in only two cycles one year apart. ...
Posted by Michael Wonder on 09 Dec 2015
New treatment options for patients with multiple sclerosis
9 December 2015 - Funding for two new medicines will provide patients with more convenient options for treating multiple sclerosis. ...
Posted by Michael Wonder on 05 Dec 2015
PHARMAC decisions relating to new multiple sclerosis treatments
4 December 2015 - PHARMAC is pleased to announce the approval of proposals to fund two new treatments for Multiple Sclerosis ...